Position in DHR
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,307,423
+$2,529,976 QoQ
Shares Held
33,267
+74.6% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.36%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DHR Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Campbell & CO Investment Adviser LLC holds $54,655,619 across 18 Diagnostics & Research names. DHR ranks #2 (11.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | A |
Agilent Technologies, Inc.
|
89,159 | $10,162,342 | |
| 2 | DHR |
Danaher Corp /De/
This page
|
33,267 | $6,307,423 | |
| 3 | WAT |
Waters Corp /De/
|
16,002 | $4,765,395 | |
| 4 | GH |
Guardant Health, Inc.
|
48,547 | $4,484,286 | |
| 5 | IDXX |
Idexx Laboratories Inc /De
|
7,772 | $4,367,009 | |
| 6 | TMO |
Thermo Fisher Scientific Inc.
|
7,448 | $3,660,915 | |
| 7 | CSTL |
Castle Biosciences Inc
|
148,824 | $3,653,629 | |
| 8 | VCYT |
Veracyte, Inc.
|
106,443 | $3,428,529 |
All Filings in DHR
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,307,423 | 33,267 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $3,777,447 | 19,053 | Shares | Sole | 2025-10-28 | |
| 2024-12-31 | $5,763,770 | 25,109 | Shares | Sole | 2025-02-10 | |
| 2024-03-31 | $1,116,747 | 4,472 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $2,411,950 | 10,426 | Shares | Sole | 2024-02-13 | |
| 2022-12-31 | $340,533 | 1,283 | Shares | Sole | 2023-02-14 | |
| 2021-09-30 | $471,881 | 1,550 | Shares | Sole | 2021-11-10 | |
| 2021-06-30 | $201,269 | 750 | Shares | Sole | 2021-08-11 | |
| No filing history on record for this holder in this stock. | ||||||